Dr. Jeremie Calais received two grants from Novartis totaling $4 million aimed at improving the effectiveness of the radiation-emitting targeted therapy 177-Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC), one of the most challenging forms of the disease. 

Read More